Alcista
$17.73
Precio del escenario
$8.440
-0.064 (-0.76%)Al cierre
DENTSPLY SIRONA Inc. is a diversified manufacturer of professional dental products and technologies. It develops, manufactures, and markets comprehensive solutions offering dental and oral health products, as well as other consumable medical devices. Its Connected Technology Solutions segment includes the design, manufacture and sales of its dental technology and equipment products. Its Essential Dental Solutions segment includes the development, manufacture and sales of the Company's value-added endodontic, restorative, and preventive consumable products and small equipment used by dental professionals for the treatment of patients. Its Orthodontic and Implant Solutions segment includes the design, manufacture, and sales of its various digital implant systems and dental implant products, digital dentures and digital orthodontic solutions. Its Wellspect Healthcare segment includes the design, manufacture, and sales of its continence care solutions for both urinary and bowel management.
DENTSPLY SIRONA Inc (XRAY) is currently trading at $8.83, which is below the average analyst price target of $12. However, the stock has experienced a significant decline of 27.68% over the past year, indicating potential ongoing challenges. The RSI is at 44.98, suggesting it is nearing oversold territory, but not quite there yet. While the company has shown some improvement in gross margin to 54.90% in Q2 2026, the forward P/E ratio is 6.33, indicating it may be undervalued. The main risk is the ongoing revenue decline, which was reported at $898 million for Q2 2026, a 4.1% decrease year-over-year, reflecting challenges in market demand.
Piper Sandler
$12
2026-10-09
Piper Sandler
2026-10-09
Precio objetivo
$12
BMO Capital
$10
2026-09-17
BMO Capital
2026-09-17
Precio objetivo
$10
Barclays
$11
2026-08-24
Barclays
2026-08-24
Precio objetivo
$11
Barrington
$15
2026-08-10
Barrington
2026-08-10
Precio objetivo
$15
BMO Capital
$13
2026-08-07
BMO Capital
2026-08-07
Precio objetivo
$13
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

Investigation into Dentsply Sirona Shareholder Rights

Wellspect Launches Surity Urinary Management System in the U.S.

Wellspect Launches Surity™ Urinary Management System for Home Use

Dentsply Sirona (XRAY) Q2 2026 Earnings Call Transcript

DENTSPLY SIRONA Reports Q2 2026 Earnings Beat Amid Revenue Decline
DENTSPLY SIRONA Inc. is a diversified manufacturer of professional dental products and technologies. It develops, manufactures, and markets comprehensive solutions offering dental and oral health products, as well as other consumable medical devices. Its Connected Technology Solutions segment includes the design, manufacture and sales of its dental technology and equipment products. Its Essential Dental Solutions segment includes the development, manufacture and sales of the Company's value-added endodontic, restorative, and preventive consumable products and small equipment used by dental professionals for the treatment of patients. Its Orthodontic and Implant Solutions segment includes the design, manufacture, and sales of its various digital implant systems and dental implant products, digital dentures and digital orthodontic solutions. Its Wellspect Healthcare segment includes the design, manufacture, and sales of its continence care solutions for both urinary and bowel management. It operates in the Healthcare sector (DENTAL EQUIPMENT & SUPPLIES industry).
DENTSPLY SIRONA Inc (XRAY) is currently trading at $8.83, which is below the average analyst price target of $12. However, the stock has experienced a significant decline of 27.68% over the past year, indicating potential ongoing challenges. The RSI is at 44.98, suggesting it is nearing oversold territory, but not quite there yet. While the company has shown some improvement in gross margin to 54.90% in Q2 2026, the forward P/E ratio is 6.33, indicating it may be undervalued. The main risk is the ongoing revenue decline, which was reported at $898 million for Q2 2026, a 4.1% decrease year-over-year, reflecting challenges in market demand.
13 analysts cover XRAY: 8 rate it Buy, 4 Hold and 1 Sell. The average price target is 13.04.
Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.